Specifically, the reduction response in Ki67 cell proliferation between core biopsy and surgery in OR-positive DCIS was seen equally in both HER-2-positive and -negative DCIS (P=0.02 and 0.03, respectively, paired samples t-test). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.